PERKINELMER INC - PKI STOCK NEWS

PerkinElmer has partnered with Ghana Health Services and the Sickle Cell Foundation to enhance neonatal screening for sickle cell disease (SCD) in Ghana. The goal is to increase screening from 4% to 50% by 2030, with a donation facilitating the capacity to screen an additional 50,000 babies yearly. Their scalable MigeleTM Gel Electrophoresis Systems are designed to support this initiative, enabling reliable and cost-effective screening. PerkinElmer aims to bolster sustainable healthcare solutions and educate communities about early SCD intervention.

PerkinElmer, a leader in life sciences, has launched the Cellaca® PLX Image Cytometry System, a groundbreaking benchtop platform for assessing multiple Critical Quality Attributes (CQAs) of cell samples. This system streamlines workflows by allowing simultaneous detection of various markers and performing rapid assays without the need for complex calibrations. Targeted especially at pharmaceutical research, particularly in CAR-T cell therapy, the Cellaca PLX promises to enhance the analysis of complex cell samples, facilitating compliance with scientific and regulatory standards.

PerkinElmer has announced FDA approval for the T-Cell Select™ reagent kit to automate the T-SPOT.TB test, enhancing lab workflow efficiency. This kit facilitates a standardized blood sample process, minimizing complex practices and allowing for room temperature storage for up to 54 hours. It is notable as the first automated IGRA TB test without regulatory warnings for immunocompromised patients. The product is set to expand access to superior latent TB testing across laboratories in the U.S. and beyond.

PerkinElmer Inc. (NYSE: PKI), a leader in health innovation, announced its participation in two significant healthcare conferences: the 2022 Wells Fargo Healthcare Conference on September 7, 2022, and Baird's 2022 Global Healthcare Conference on September 13, 2022. CEO Prahlad Singh will lead 30-minute fireside chats at both events, detailing the company’s strategic focus. Interested parties can access live webcasts and replays via the Investor section of PerkinElmer's website, ensuring availability for 90 days after each presentation.

Max Krakowiak has been appointed as the new Chief Financial Officer of PerkinElmer (NYSE:PKI), succeeding Jamey Mock, who is leaving for another opportunity. The transition is effective as of September 6, 2022. Krakowiak has been with PerkinElmer for four years, serving as the Vice President of Corporate Finance and has led key financial initiatives. The company reaffirms its financial guidance provided on August 1, 2022. CEO Prahlad Singh expressed confidence in Krakowiak's capabilities and acknowledged Mock's contributions during his tenure.

New Mountain Capital has announced a definitive agreement to acquire PerkinElmer's Applied, Food, and Enterprise Services businesses for up to $2.45 billion. This acquisition includes OneSource laboratory services and various scientific instruments serving multiple markets, including biopharma and food safety. The deal is expected to close in Q1 2023, pending regulatory approvals. Both companies believe this partnership will enhance strategic growth and innovation in their sectors.

PerkinElmer (NYSE: PKI) reported Q2 2022 revenue of $1.23 billion, unchanged from last year, with GAAP EPS from continuing operations at $1.42, down from $2.19 a year ago. The company initiated Q3 guidance of approximately $1.02-1.03 billion in revenue and adjusted EPS of $1.40-1.45, while raising full-year guidance to $4.60-4.64 billion and adjusted EPS of $7.80-7.90. PerkinElmer also announced an agreement to divest its Applied, Food, and Enterprise Services businesses for $2.45 billion, expected to close in Q1 2023.

PerkinElmer has signed an agreement to divest its Applied, Food, and Enterprise Services businesses to New Mountain Capital for $2.45 billion. Of this, $2.30 billion will be received at closing, with $150 million contingent on future valuations. Post-transaction, PerkinElmer will focus solely on Life Sciences and Diagnostics, projected to generate $3.3 billion in 2022 revenue, with over 10% annual organic growth. The divestiture is expected to close in Q1 2023.

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) has declared a regular quarterly dividend of $0.07 per share. This dividend is set to be paid on November 11, 2022, to shareholders of record as of the close of business on October 21, 2022. In 2021, the company reported revenue of approximately $5 billion and employs over 16,000 people globally. PerkinElmer is committed to innovation for a healthier world and is a component of the S&P 500 Index.